Lancet Oncology

Article	Citations
Health insurance system in Japan faces risk of politicisation	930
Navigating the complexity: reflections on the development of perioperative cancer treatments	690
Dual therapy in metastatic castration-resistant prostate cancer	615
US FDA proposes stronger laboratory test oversight	587
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	521
Toxicity assessment bias in the PACE-C trial – Authors' reply	461
New national cancer registry for France	457
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX	434
The future of precise cancer chronotherapeutics	407
Palliative radiotherapy for hepatic cancer pain	379
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply	359
SANO trial: innovations, risks, and unanswered questions	353
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	352
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	348
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	335
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	319
Olanzapine for chemotherapy-induced nausea and vomiting control	308
Study bolsters concerns about US FDA accelerated drug approvals	307
Survivorship after neoadjuvant chemotherapy	270
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	259
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	253
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	250
Combination immunotherapy in chemotherapy in gastric cancer	249
Correction to Lancet Oncol 2022; 23: 1124–26	248
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC	245

Use of artificial intelligence to enhance detection of nodal metastases	245
Patients with cancer in Louisiana denied fertility preservation cover	231
A new generation of comprehensive precision oncology trials	228
The GLOW trial in chronic lymphocytic leukaemia	225
Medical treatment for active breast cancer brain metastases	224
Precision medicine for children with cancer	220
Concern for cancer drugs in USA–EU tariff war	217
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	216
IVLBCL mimicking VEXAS syndrome	215
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	214
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply	213
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	204
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	202
Determining the optimal use of approved drugs in oncology	201
Italy to pass law on the right to be forgotten for cancer survivors	197
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o	195
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	190
The silent malignant mesothelioma epidemic: a call to action	186
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas	185
Correction to Lancet Oncol 2021; 22: 1081–92	184
US Surgeon General calls for cancer warning labels on alcohol	181
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	179
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	176
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	176
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	175
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	173
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	173
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	172
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	172
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial	170
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus	160
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	159
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	158
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	157
Innovation in gynaecological cancer: highlighting global disparities	155
Focus where it matters: turning insights into advocacy	154
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	153
Syrian cancer patients regain treatment access in Türkiye	147
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	147
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	147
Mantle cell lymphoma: is it time for risk-adapted treatment?	145
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	143
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	143
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	142
Challenges and prospects for cancer treatment in prison settings	140
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	139
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	134
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	132
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	131
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	131

De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer	130
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	128
Cancer on the agenda during IAEA Director General's visit to Chile	127
Balancing clinical benefit and social value: challenges in HTA assessments	125
Lung cancer rates highest among British Bangladeshi men	125
Correction to Lancet Oncol 2023; 24: e242	122
Radiotherapy and conflict: from disruption to expansion and hope	121
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	115
Clearing the radiotherapy backlog: innovation to pave the way	114
A biobank perspective on use of tissue samples donated by trial participants	112
2022 ASTRO annual meeting	112
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	112
Common Sense Oncology: including everyone	112
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	111
Decentralised, point-of-care CAR-T for multiple myeloma	109
Correction to Lancet Oncol 2020; 21: 699–709	108
Importance of clinical research for the UK's 10-year cancer plan	107
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	107
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	107
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	107
Essential anticancer medicines for children: defining what matters most for Europe	104
Oral contraceptives and risk of liver cancer	103
WHO reports health service disruptions due to suspensions of aid	102
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	100
Systemic therapy for brain metastases: a changing landscape	99
Daratumumab maintenance in patients with myeloma	98
Antimicrobial resistance in patients with haematological malignancies: a scoping review	98
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	97
ESMO Congress 2025	93
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials	91
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	89
India rolls out HPV vaccination	87
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	87
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	86
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	85
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	85
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	84
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	84
Correction to Lancet Oncol 2024; 25: e126–35	83
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	83
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	82
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	82
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	81
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	81
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	81
Medical debt of people with cancer in the USA	81
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	81
Transforming cancer: behind the scenes at the Crick Institute	80
Correction to Lancet Oncol 2023; 24: 1181–95	80
Endometrial cancer: the individual approach	80
Managing immune checkpoint inhibition in transplant recipients	79
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	79
Progress in global tobacco control measures	79
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label,	78
A red patch on the palate	78
ROAR trial: which treatment is effective after progression?	77
Promoting cancer prevention through World Cancer Day in Nigeria	77
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	77
AACR Annual Meeting 2023	76
Mozambique takes on cancer burden challenges	76
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	76
Screening for breast cancer brain metastases	75
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA	75
Internationally trained doctors in the USA	75
South Africa's new tobacco and e-cigarette control bill	75
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting	75
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	75
On a precipice: the UK's broken health-care system	74
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	74
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	73
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose	73
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	72
Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice	72
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	72
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	71
The importance of preventing occupational cancer	71
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	71
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	70
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	69
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-lab	68

Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	68
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	67
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	67
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	66
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	65
Stereotactic ablative radiotherapy for primary kidney cancer	64
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	64
Challenging cancer through poetry	64
Anticipating the future of cancer care in Trump's America	63
American Lung Association calls for expanded insurance coverage for lung cancer screening	63
Rwanda provides free treatment to all cancer patients	63
US legislation might soon allow easier access to cancer medications	62
PSMA-PET research: addressing challenges and prospects – Authors' reply	62
Sharing a personal story behind brain cancer	61
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	61
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	61
US Clean Air in the firing line	61
Sharp increase in patients waiting months for urgent cancer treatment	61
Delay to England's National Cancer Plan could cost lives	59
Between the lines: an oncology diary no one assigned	59
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	58
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	58
Sharing experiences and forming bonds at the Edinburgh Fringe	58
Abemaciclib for malignant pleural mesothelioma – Authors' reply	58
Correction to Lancet Oncol 2022; 23: 1297–307	57
US lawmakers call on Biden Administration to lower the price of enzalutamide	57
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	57
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	56
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study	56
Correction to Lancet Oncol 2016; 17: 484–95	56
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	55
Correction to Lancet Oncol 2023; 24: 91–106	55
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	55
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	54
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	54
Correction to Lancet Oncol 2023; 24: e472–518	54
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	54
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	53
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	53
Code of practice needed for samples donated by trial participants – Sponsor's reply	53
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed	53
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	52
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	52
Quality control and childhood cancer medicines	52
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial	52
Qatar national cancer care and research: pioneering strategies for global health excellence	52
San Antonio Breast Cancer Symposium 2025	52
Problems with catch-up HPV vaccination after resumption of proactive recommendations	51
Essential medicines list in national cancer control plans: a secondary analysis from a global study	51
Correction to Lancet Oncol 2025; 26: 548–49	51
HPV vaccine roll-out in Nigeria and Bangladesh	51
WHO calls for investment in cancer prevention and care within a wider NCD strategy	51
US cancer research might never recover from proposed Trump funding cuts	51
Management of locally advanced gastric cancer	51
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	51
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	50
The changing global landscape of national cancer control plans	49
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	49
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label	49
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, op	49
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	49
Immunotherapy: balancing the risks and benefits	48
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	48
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-	48
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	48
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	47
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resul	47
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	47
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	47
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	46
New evidence for brain cancer risk after a single paediatric CT scan	46
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	46
Improved cancer coverage for firefighters in Western Australia	45
Indonesia and the Philippines take steps to control cancer	45
Correction to Lancet Oncol 2024; 25: 317–25	45
Correction to Lancet Oncol 2024; 25: 744–59	44
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	44
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	44
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	44
Correction to Lancet Oncol 2022; 23: 416–27	44
BrECADD and fertility: an ongoing concern	43
2025 ASCO Annual Meeting	43
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm	43
BrECADD and fertility: an ongoing concern – Authors' reply	43
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer	43
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma	42
US mRNA cancer vaccine research faces an uncertain future	42
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?	42
FDA decisions on new oncological drugs	42
Reflections on the PEACE V–STORM trial	42
Correction to Lancet Oncol 2024; 25: 1625–34	41
The BREAKING-ICE App: an interactive journey into informative censoring	41
Capturing the true effect of anti-PD-1 therapy on patients’ health-related quality of life	40
Solutions for tackling the global surgery crisis in west Africa	40
The impact of armed conflict on global patterns of childhood cancer	40